文献速递乳腺癌胸部肿瘤消化系统肿瘤

难治性转移性癌症的整合泛癌基因组与转录组分析

Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer.
PubMed 文献 · Cancer Discov · 2023-01-01

研究分析泛癌队列META-PRISM中1031例难治性转移性肿瘤的全外显子与转录组测序,发现标准治疗耐药生物标志物仅见于肺癌和结肠癌(占9.6%),分子标志物可改善6个月生存预测,尤其在晚期乳腺癌患者中。

要点

  • META-PRISM队列中标准治疗耐药标志物仅见于肺癌和结肠癌,占9.6%。
  • 治疗患者中多种研究性或假设性耐药机制较未治疗患者富集。
  • 分子标志物改善6个月生存预测,尤其在晚期乳腺癌患者中。

核心结论

  • META-PRISM队列可用于研究耐药机制并进行预测分析。
  • 标准治疗中解释耐药的标志物匮乏,研究性和假设性标志物有待进一步验证。
  • 分子谱分析在晚期癌症尤其是乳腺癌中有助于改善生存预测和评估I期临床试验资格。

研究设计与样本

  • 泛癌队列META-PRISM分析1031例难治性转移性肿瘤,采用全外显子与转录组测序。

主要发现

  • META-PRISM肿瘤尤其前列腺、膀胱和胰腺类型,与未治疗原发肿瘤相比显示最广泛变异的基因组。
  • 标准治疗耐药生物标志物仅见于肺癌和结肠癌,占META-PRISM肿瘤的9.6%。
  • 治疗患者较未治疗患者富集多种研究性和假设性耐药机制,验证其推定的耐药作用。
  • 分子标志物改善6个月生存预测,尤其在晚期乳腺癌患者中。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Metastatic relapse after treatment is the leading cause of cancer mortality, and known resistance mechanisms are missing for most treatments administered to patients. To bridge this gap, we analyze a pan-cancer cohort (META-PRISM) of 1,031 refractory metastatic tumors profiled via whole-exome and transcriptome sequencing. META-PRISM tumors, particularly prostate, bladder, and pancreatic types, displayed the most transformed genomes compared with primary untreated tumors. Standard-of-care resistance biomarkers were identified only in lung and colon cancers-9.6% of META-PRISM tumors, indicating that too few resistance mechanisms have received clinical validation. In contrast, we verified the enrichment of multiple investigational and hypothetical resistance mechanisms in treated compared with nontreated patients, thereby confirming their putative role in treatment resistance. Additionally, we demonstrated that molecular markers improve 6-month survival prediction, particularly in patients with advanced breast cancer. Our analysis establishes the utility of the META-PRISM cohort for investigating resistance mechanisms and performing predictive analyses in cancer. SIGNIFICANCE: This study highlights the paucity of standard-of-care markers that explain treatment resistance and the promise of investigational and hypothetical markers awaiting further validation. It also demonstrates the utility of molecular profiling in advanced-stage cancers, particularly breast cancer, to improve the survival prediction and assess eligibility to phase I clinical trials. This article is highlighted in the In This Issue feature, p. 1027.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Pradat Y, Viot J, Yurchenko AA, et al. Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer. Cancer Discov. 2023. PMID: 36862804. doi:10.1158/2159-8290.CD-22-0966

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。